Financing ·
Cabaletta Bio reported the exercise of warrants issued during its June 2025 underwritten public offering
CABACabaletta Bio, Inc.
Cabaletta Bio reported the exercise of warrants issued during its June 2025 underwritten public offering. From issuance through June 30, 2026, 5,275,100 warrants were exercised for approximately $13.2 million in gross proceeds. Between July 1, 2026 and the expiration date of September 12, 2026, an additional 46,011,900 warrants were exercised, generating approximately $115.0 million in gross proceeds. The total aggregate gross proceeds from all warrant exercises amount to approximately $128.2 million. Cabaletta Bio operates in the biotechnology industry, focusing on developing immunotherapies for cancer treatment.